P. Edlund

发表

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

J. Bergh, C. Blomqvist, H. Mouridsen, 2011, Acta oncologica.

Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer.

J. Bergh, H. Mouridsen, M. Ewertz, 2007, European journal of cancer.

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

J. Bergh, P. Malmström, S. Margolin, 2011, Acta oncologica.

Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1

J. Bergh, C. Blomqvist, M. Andersson, 2020, Acta oncologica.

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

J. Bergh, S. Margolin, N. Bengtsson, 2017, Breast Cancer Research and Treatment.

Radiosensitizing biological modifiers enhancing efficacy in non-small-cell lung cancer treated with radiotherapy

R. Henriksson, D. Brattström, M. Bergqvist, 2013 .

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

J. Bergh, H. Mouridsen, B. Nordenskjöld, 2008, Acta oncologica.

Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.

D. Brattström, M. Bergqvist, S. Ekman, 2015, Anticancer research.

Inter-observer variation in delineating the coronary arteries as organs at risk.

C. Blomqvist, P. W. Nyström, H. Garmo, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.

J. Bergh, H. Mouridsen, N. Bengtsson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer on the Internet: the quality of Swedish breast cancer websites.

Gerhard Andersson, Carl Blomqvist, Per Edlund, 2004, Breast.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

F. van Coevorden, K. Sikorska, J. V. van Sandick, 2018, The Lancet. Oncology.

A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer.

J. Bergh, C. Blomqvist, M. Andersson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.